Clinical trial LPS14201 ? CARD
A randomized, open label, multicenter study of Cabazitaxel versus an Androgen Receptor (AR)-targeted agent (abiraterone or enzalutamide) in mCRPC patients previously treated with Docetaxel and who rapidly failed a prior AR-targeted agent (CARD)
| Cancers | |
|---|---|
| Organ | prostate |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Sanofi-Aventis |
| EudraCT Identifier | 2014-004676-29 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02485691 |
| Inclusion criteria | Metastatic castration resistant prostate cancer after progression to docetaxel and androgen-receptor targeted agent. |
| Last update |